Evonik Corporate Venturing

Dr. Jürgen Finke

Ecosummit 2012, Neuss November 14, 2012



Focus on specialty chemicals




- Evonik is one of the global leaders in specialty chemicals
- Strong integrated technology platforms
- Balanced spectrum of business activities and end-markets
- Close collaboration with customers
- Market-oriented research and development



A worldwide presence





Key figures 2011



€14.5 billion
€13.0 billion
€0.4 billion
€2.8 billion
19.0 %
18.7 %
33,556

Evonik Corporate Venturing



- Evonik Corporate Venturing is the venture capital arm of Evonik Industries AG, one of the world's leading providers of specialty chemicals.
- We make medium-term investments in start-ups and venture capital funds throughout the world, with total volumes reaching €100 million.
- We are a strategic investor that actively collaborates with its portfolio companies helping implement the Evonik open innovation strategy and leveraging the strengths of Evonik to drive growth at portfolio companies.



Corporate Venturing Supports Evonik's Open Innovation Concept




- 1. Observe transformations of industry segments in an early stage and provide options.
- 2. Complementary add-on to in-house research to be able to compete in today's global markets.
- 3. The venture capital industry plays a central role in:
 - funding entrepreneurs i.e. start-ups that develop disruptive innovations.
 - build relationships to large corporations.



Corporate Venturing supports the growth strategy of Evonik





Our basic investment focus



We invest in young companies with innovative technology and high growth potential in the field of specialty chemicals, companies with solutions to problems within the following megatrends:

- Resource efficiency
- Health & Nutrition
- Globalization







What we ask for



We are a partner with strategic objectives for innovative, market-oriented technology companies with

- a clear growth strategy
- a highly motivated, focused management team
- a clear, distinctive selling point
- a secure IP position



Our basic terms



We generally maintain a minority share and typically invest up to EUR 5 million per company

- in early-stage companies with an established proof of concept, typically in series A & B rounds
- in companies that have already entered the market or are about to do so
- typically in syndication with other venture capital investors



What we contribute



Successfully implementing a growth strategy requires more than just money.

Evonik as one of the world's leading providers of specialty chemicals brings additional strategic capabilities to the partnership.

- Technological expertise and infrastructure
- Market experience and access
- A global distribution network
- Expertise in patent strategies and on issues of industrial property rights

We focus of our global investments on Europe, the U.S., and Asia.





Thank you for your attention!

Dr. Jürgen Finke
Evonik Corporate Venturing
Investment Manager
+49 (0)201 177 4420
juergen.finke@evonik.com

